摘要
目的:了解北京医院住院患者利伐沙班的应用情况,总结临床用药经验,为规范其临床应用提供参考。方法:检索北京医院治疗药物监测系统,查阅2012年1月至2016年12月应用利伐沙班的住院患者,对病例进行系统的回顾性分析,并对调查结果进行统计分析。结果:共纳入患者768例,平均年龄为(72.9±12.0)岁。其中≥65岁患者占76.6%(602/786)。平均住院时间为(16.9±9.0)d。有656例(83.5%)在住院期间行手术治疗,其中接受人工膝/髋关节置换术的患者数量最多,占所有接受手术患者的51.4%(337/656)。利伐沙班用量在5~30 mg·d-1之间,平均(11.0±3.7)mg·d^(-1),647例患者为手术后短期服用利伐沙班抗凝治疗,占82.3%;139例长期服用利伐沙班抗凝治疗,占17.7%,其中48例本次入院首次服用,91例本次入院前已经服用。结论:利伐沙班为可口服的凝血因子Ⅹa直接抑制剂,具有剂量固定、起效快速、治疗窗宽、无需监测、与食物药物相互作用小等优点。在抗凝治疗中具有很好的应用前景。
Objective： To investigate the clinical application of rivaroxaban in inpatients of Beijing Hospital,and provide reference for Its standardized application. Methods： A retrospective analysis was conducted on patients who were treated with rivaroxaban in Beijing Hospital from January 2012 to December 2016 using PASS system. Results： A total of 786 patients were enrolled with an average age of（72.9±12.0） years. Patients over 65 years old accounted for 76.6%（602/786）. The average length of hospital stay was（16.9±9.0） days. There were 656（83.5%）cases undergoing surgery during hospitalization. Patients undergoing artificial knee/hip arthroplasty accounted for 51.4%（337/656） of all patients undergoing surgery. Rivaroxaban was administered at the dose of 5 mg·d^（-1） to 30 mg·d^（-1） with an average value of（11.0±3.7） mg·d^（-1）. A total of 647 patients were treated with rivaroxaban shortly after surgery, accounting for 82.3% of the enrolled subjects. Of the 139（17.7%） patients who took rivaroxaban for a long time, 48 took the medication for the first time after being admitted, and 91 had been taking it before the admission. Conclusion： Rivaroxaban is a direct inhibitor of factor Ⅹa. It has good tolerability, few drug-drug interactions and adverse reactions. Rivaroxaban is expected to become a safe and effective oral anticoagulant.
作者
朱愿超
赵紫楠
梁良
陈頔
赵明
张亚同
ZHU Yuan-chao;ZHAO Zi-nan;LIANG Liang;CHEN Di;ZHAO Ming;ZHANG Ya-tong(Department of Pharmacy, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing Hospital, National Center of Gerontology, Beijing 100730, China)
出处
《临床药物治疗杂志》
2018年第4期58-61,共4页
Clinical Medication Journal
